Seeking Alpha
18 Nov 2026, 21:42 UTC · 1h ago
Alpha Tau Medical: The Rubber Meets The Road In H1 2027
Impact · against what's priced in
DRTS remains a speculative bet on a 2027 regulatory catalyst, with its current valuation supported by a strong cash position and early clinical signals. The news is largely a confirmation of existing milestones rather than a new catalyst.
- DRTS+0.20
No priced-in read yet
- In context
The target for FDA approval in recurrent SCC skin cancer in H1 2027 and a $100.6 million cash reserve provide a clear timeline and funding bridge for the microcap's primary catalyst.
Read from the article alone





